Ezell Antoine C
Known title: EVP, President, NA & CMOCIK: 0001826528
Associated companies
Transaction History
| BDX | ▲ Buy | Grant | 1,388 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 2,619 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,357 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 282 | $0 | 3/1/2024 | View on chart |
| BDX | ▲ Buy | Grant | 956 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Grant | 3,113 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,654 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 650 | $0 | 3/2/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 418 | $0 | 3/1/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,045 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 115 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 610 | $0 | 3/2/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 276 | $0 | 3/1/2022 | View on chart |
| BDX | ▲ Buy | Grant | 758 | $0 | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.